Axsome Therapeutics, Inc. (AXSM) News Headlines

5/18/2022 7:00:00 AM Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry (Press Release)

5/9/2022 7:36:00 AM Jazz Pharma Completes U.S. Divestiture Of Sunosi To Axsome Therapeutics

5/3/2022 4:35:23 AM TCMD Expects 13-15% Revenue Growth In 2022, AXSM On Watch, QURE Awaits Huntington's Trial Data

5/2/2022 7:30:45 AM Axsome Therapeutics Gets FDA CRL For AXS-07 NDA For Acute Treatment Of Migraine

5/2/2022 7:10:06 AM Axsome Therapeutics Q1 Net Loss $39.6 Mln Vs. Net Loss $29.3 Mln Last Year

5/2/2022 7:07:03 AM Axsome Therapeutics Gets FDA Complete Response Letter For NDA For AXS-07 For Acute Treatment Of Migraine

5/2/2022 7:05:00 AM Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (Press Release)

4/25/2022 10:51:39 AM Axsome Stock Tanks 20% As The Co. Expects FDA's CRL For AXS-07 For Acute Treatment Of Migraine

4/19/2022 10:48:49 AM Axsome Therapeutics Stock Jumps 22% As The Co. Anticipates FDA Approval Of Its Depression Drug In Q2

4/19/2022 7:59:31 AM Pre-market Movers: AXSM, SST, SAVA, ENSV, SMCI…

3/28/2022 10:53:02 AM Axsome Therapeutics Gains On Acquisition Of Sunosi From Jazz Pharma

3/28/2022 6:58:19 AM Axsome To Buy Sunosi From Jazz

3/28/2022 6:12:19 AM Axsome Therapeutics Enters Agreement To Acquire Sunosi From Jazz Pharma

3/28/2022 1:31:43 AM Biotech Stocks Facing FDA Decision In April 2022

9/16/2021 7:56:48 AM Axsome Therapeutics Initiates SYMPHONY Phase 3 Trial Of AXS-12 In Narcolepsy

9/14/2021 7:53:10 AM Axsome Therapeutics Says FDA Accepts AXS-07 NDA For Acute Treatment Of Migraine - Quick Facts

9/14/2021 7:41:52 AM Axsome Therapeutics: FDA Accepts AXS-07 NDA For Acute Treatment Of Migraine